Business Description
aTyr Pharma Inc
NAICS : 325414
SIC : 2836
ISIN : US0021201035
Description
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.67 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.23 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -4.23 | |||||
| Beneish M-Score | 13.77 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -81.7 | |||||
| 3-Year EBITDA Growth Rate | 15.3 | |||||
| 3-Year EPS without NRI Growth Rate | 19 | |||||
| 3-Year FCF Growth Rate | 25.6 | |||||
| 3-Year Book Growth Rate | -20.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 60.96 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 604.81 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.7 | |||||
| 9-Day RSI | 34.25 | |||||
| 14-Day RSI | 39.71 | |||||
| 6-1 Month Momentum % | -2.31 | |||||
| 12-1 Month Momentum % | 14.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.63 | |||||
| Quick Ratio | 7.63 | |||||
| Cash Ratio | 6.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -79.1 | |||||
| Shareholder Yield % | -24.11 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -10633.5 | |||||
| Net Margin % | -9846.43 | |||||
| FCF Margin % | -10831.63 | |||||
| ROE % | -62.75 | |||||
| ROA % | -48.44 | |||||
| ROIC % | -341.07 | |||||
| 3-Year ROIIC % | -261.22 | |||||
| ROC (Joel Greenblatt) % | -454.89 | |||||
| ROCE % | -59.19 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 177 | |||||
| PB Ratio | 1.64 | |||||
| Price-to-Tangible-Book | 1.63 | |||||
| EV-to-EBIT | -1.11 | |||||
| EV-to-Forward-EBIT | -0.96 | |||||
| EV-to-EBITDA | -1.16 | |||||
| EV-to-Forward-EBITDA | -0.96 | |||||
| EV-to-Revenue | 118.24 | |||||
| EV-to-Forward-Revenue | 3.76 | |||||
| EV-to-FCF | -1.09 | |||||
| Price-to-Net-Current-Asset-Value | 2.03 | |||||
| Price-to-Net-Cash | 2.49 | |||||
| Earnings Yield (Greenblatt) % | -90.09 | |||||
| FCF Yield % | -47.74 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers